Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
The University of Oxford and Selvita Collaborate to Advance Potential Therapeutics for Parkinson's Disease
The University of Oxford and Selvita, one of the largest contract research organizations in Europe, […]
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
HanAll Biopharma and Daewoong Pharmaceutical announced that they have entered into a co-development agreement with NurrOn […]
Verana Health Announces the Qdata Parkinson's Disease Module at 2023 AAN Annual Meeting
Verana Health, a digital health company elevating quality in real-world data (RWD), has announced it’s […]
AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson's Disease
Asklepios BioPharmaceutical (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary […]
BlueRock Therapeutics to use Rune Labs' Clinical Trial Platform to Better Characterize Parkinson's Disease State in Cell Therapy Trials
Rune Labs, a precision neurology software and data platform company, today announced a partnership with […]
Celltrion and LISCure Biosciences Announce Strategic Collaboration to Develop Novel Microbiome Treatment for Parkinson's Disease
LISCure Biosciences, a clinical-stage biotech developing advanced microbiome technology with precision targets, announced a multi-year […]
Ryne Biotechnology Awarded $4 Million from the California Institute for Regenerative Medicine
Ryne Biotechnology, a therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to discover and […]
MedRhythms Feasibility Study Shows Positive Topline Results in Parkinson's Disease
MedRhythms announced the successful completion of a multi-site feasibility study of MR-005, its investigational asset […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more